Abstract
e11521 Background: BV is a targeting vascular endothelial growth factor that is used in combination with chemotherapy (CTX) in a variety of advanced metastatic cancers. Methods: We used P as the standard upfront CTX along with BV to treat 10 patients aged 33-60 (mean age 44.2.) 100% Her2 /Neu negative ; 30% triple negative with WDMBC. (Metastatic sites listed in Table.) Treatment regime was P (175 mg/m2) and BV (15 mg/kg) every 3 weeks. The patients were followed for overall survival (OS); response rate (RR); and progression-free survival (PFS) over a 28-month period. Evaluation was via MRI, PET CT and spinal tap. Results: 2 patients (20%) achieved complete remission; 6 (60%) achieved partial remission; and 1 (10%) has stable disease. 2 (20%) died. OS was 80%. Median survival time was 9 months. Median number of cycles given was 13. Median time between starting treatment and documented remission was 5 months. Skin lesions disappeared after a median of 5 cycles. One patient with meningeal and brain metastases achieved CR after 10 cycles and remained disease free for 8 months without any radiation therapy to the meninges or brain. Side effects included mild neuropathy (80%), hematological toxicities (60%), and transient ischemic attack (10%). Performance status of the 8 surviving patients is 0. Conclusions: Patients with WDMBC receiving P and BV can experience disease regression and disappearance of metastases including meningeal and brain lesions. There are few reports in the literature documenting complete remission of meningeal and metastatic brain lesions without radiotherapy. Our promising results suggest that this combined therapy be evaluated in larger patient numbers to determine whether this regime might alleviate the need for radiotherapy to the meninges and brain in WDMBC patients. Site of metastases Bone Lung Liver Skin Brain Adrenal Meninges No. of patients 9 7 3 3 2 2 1 No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
